Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × niraparib × 1 year × Clear all

Sponsor

Conditions

Ovarian Neoplasms 21 Breast Neoplasms 11 Prostatic Neoplasms 10 Fallopian Tube Neoplasms 8 Neoplasms 7 Neoplasm Metastasis 7 Pancreatic Neoplasms 6 Triple Negative Breast Neoplasms 4 Glioblastoma 4 Endometrial Neoplasms 4 Lung Neoplasms 3 Glioma 3 Carcinoma, Ovarian Epithelial 3 Small Cell Lung Carcinoma 2 Recurrence 2 Prostatic Neoplasms, Castration-Resistant 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1 Sarcoma 1 SCLC,Extensive Stage 1 Rectal Neoplasms 1 Prostate Carcinoma Metastatic to the Bone 1 Prostate Adenocarcinoma 1

Interventions

fludarabine 4 Cisplatin 4 atezolizumab 3 Pemetrexed 3 Cyclophosphamide 3 pralsetinib 2 pembrolizumab 2 fludarabine phosphate 2 entrectinib 2 durvalumab 2 cobimetinib 2 capmatinib 2 alectinib 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Paclitaxel 2 Nivolumab 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Busulfan 2 130-nm albumin-bound paclitaxel 2 trametinib 1 spartalizumab 1 ruxolitinib 1 repotrectinib 1 ponatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡